Navigation Links
Human Pheromone Sciences Announces Fourth Quarter and Full Year Results
Date:3/27/2009

SAN JOSE, Calif., March 27 /PRNewswire-FirstCall/ -- Human Pheromone Sciences, Inc. (OTC Bulletin Board: EROX) ("HPS" or "the Company") today announced results for the three months and the year ended December 31, 2008. For the three months ended December 31, 2008, net revenue was $228,000, representing a 41% decrease from revenues of $389,000 in the prior year period, and resulted in net loss of $(58,000) ($(0.01) per share) as compared with net income of $38,000 ($0.01 per share) for the same period in 2007. For the full year, net revenues of $992,000, were 23% less than revenues of $1,291,000 generated in the prior year. The net loss in the current year of $239,000 ($0.06 per share) was $223,000 higher than the $16,000 loss ($.00 per share) recorded for the full year of 2007. Net cash utilized for the full year of 2008 was $530,000, less than a 5% increase from the $501,000 utilized in the year 2007.

"The revenue reduction in the fourth quarter and the full year was attributable to a significant reduction in purchases by our largest and first multinational licensee of pheromones. Over the past 10 years we have been principally dependent on purchases by this customer for revenue generation. Total product revenues decreased by approximately 50% from this customer in 2008," a spokesperson noted.

"Over the past couple of years, we developed a multi-faceted program to be less dependent on any one customer, seek additional licensees in the U.S. and abroad for our original pheromone technologies, complete scientific validation on our most promising mood-enhancing compound and present the results to consumer marketers. With respect to the first strategic imperative, during 2008, licensing revenue increased to $604,000, a 15% growth from the prior year, primarily attributable to new agreement with a multinational corporation. Discussions are ongoing with potential licensees and we are also in discussions to broaden the channels of distribution for our initial pheromone compounds. With respect to the second area of focus, the discovery and patented protection of new mood-enhancing compounds, the Company filed a final U.S. Patent Application and a European filing for a compound that has shown significantly enhanced positive feelings and emotions in both men and women. We are currently presenting the results of the human studies on ER 303 to several multinational consumer products companies. In addition, the Company completed initial toxicology testing and initial human response studies on another compound for women, and we have identified and selected six additional compounds that have shown promise in initial laboratory studies."

"We believe that focus on these basic strategic imperatives will lessen our dependence on the purchasing pattern of one large customer, and ensure balanced growth in revenue and an expanded technology and customer base, without major capital investment," the spokesman further stated.

Human Pheromone Sciences, Inc. is a technology-based company, whose proof-of-concept products included prestige-priced fragrances and toiletries and environmental products sold under the REALM(R), innerREALM(R) and EROX(R) trademarks. These products, and its Natural Attraction(R) product line, contain mood-enhancing synthesized human pheromones covered under U.S. and foreign patents. The Company also licenses its proprietary technology to other companies for inclusion in their products for direct sale to the consumer. Scientific and consumer studies have shown that the Company's human pheromones positively impact on the moods, attitudes and emotions of wearers. Further information is available online at www.erox.com.

The statements in this news release may contain forward-looking statements that involve risks and uncertainties that could cause actual results to differ from predicted results. Further information on factors that could affect the Company's results is detailed in the Company's annual report to shareholders on Form 10-K for the year ended December 31, 2008 as filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements.

                          HUMAN PHEROMONE SCIENCES, INC.
                            Condensed Balance Sheets
                             (Dollars in thousands)

                                            December 31,          December 31,
                                               2008                  2007

    Assets

    Cash and cash equivalents             $         907       $         1,437
    Accounts receivable                              52                   194
    Inventories, net                                 39                    25
    Other current assets                             58                    40
    Property and equipment, net                       2                     3
                                          -------------       ---------------

    Total                                 $       1,058       $         1,699
                                          =============       ===============

    Liabilities and Shareholders' Equity

    Accounts payable                      $          19       $           28
    Other current liabilities                       131                  141
    Deferred income - current                       297                  518
    Deferred income - non-current                   324                  566
    Common stock                                 21,043               20,963
    Accumulated deficit                         (20,756)             (20,517)
                                          -------------       ---------------

    Total                                 $       1,058       $        1,699
                                          =============       ===============



                          HUMAN PHEROMONE SCIENCES, INC.
                        Condensed Statements of Operations
                  (Dollars in thousands, except per-share data)

                                    Three months                 Year
                                 ended December 31,        ended December 31,
                                 2008         2007         2008         2007

    Net revenues               $  228       $  389       $  992     $  1,291

    Cost of goods sold             82           99          322          376
    Research and development       14           11           47           49
    Selling, general and
     administrative               193          256          889          942
                               ------       ------       ------     --------

    Income (loss) from
     operations                   (61)          23         (266)         (76)

    Other income                    5           15           30           65
                               ------       ------       ------     --------

    Income (loss) before
     provision for income taxes   (56)          38         (236)         (11)

    Provision for Income taxes      2            -            3            5
                               ------       ------       ------     --------

    Net income (loss)          $  (58)      $   38       $ (239)    $    (16)
                               ======       ======       ======     ========



    Net income (loss)
     per share -

         Basic                 $(0.01)      $ 0.01       $(0.06)    $  (0.00)
         Fully diluted         $(0.01)      $ 0.01       $(0.06)    $  (0.00)

    Weighted average number
     of shares -

         Basic                  4,152        4,152        4,152        4,152
         Fully diluted          4,152        4,852        4,152        4,152


    Net income (loss) per share is based on the weighted average number of
    common shares and common equivalents outstanding during each period.
    Certain common stock equivalents are excluded when their effect would be
    anti-dilutive.


'/>"/>
SOURCE Human Pheromone Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Federal funding gap cited for research on human health impacts due to climate change
2. Human papillomavirus genotype distribution in New Mexico cervical cancers
3. Human Brain Works Between Order and Chaos
4. The human tragedy of denying AIDS
5. Research Finds Popular Household Pets Transmit Dangerous Parasites to Humans
6. Chicago's Own Hacker Con Set for May, Teaches Human Hacking to Corporations
7. University of Pennsylvania researchers find that the unexpected is a key to human learning
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Cowen Conference
9. The Heart Foundation Honors Celebrity Chef Wolfgang Puck With The Steven S. Cohen Humanitarian Award
10. Beaumont Launches 1st U.S. Adult Human Stem Cell Study for Stress Urinary Incontinence
11. Global War on Drugs Takes Devastating Toll on Human Lives, Advocates Say
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... First ... compliance program management, will showcase a range of technology and learning solutions at ... (NCAL) Convention and Expo to be held October 14–18, 2017 at the Mandalay ...
(Date:10/12/2017)... ... 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of ... innovative new design of the shoulder pad. The shoulder pad provides optimal support ... your pain while using cold therapy. By utilizing ice and water that is circulated ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... has recently contributed a medical article to the newly revamped Cosmetic Town ... article spotlights the hair transplant procedure known as Follicular Unit Extraction ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand Rapids-based ... and Brightest in Wellness® by Best and Brightest. OnSite Wellness will be honored ... 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection Hotel, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Farm Forward joins ... other leading institutions in announcing the launch of the Leadership Circle , ... animals are raised for food. , Founding members of the Leadership Circle also ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... MENLO PARK, Calif. , Oct. 11, 2017 /PRNewswire/ ... a national scientific team that developed an innovative way ... and quantity of the delivery of new drugs. ... the 2017 Fall Clinical Dermatology Conference will show how ... Massachusetts General Hospital, Harvard Medical School used a suite ...
(Date:10/11/2017)...  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today provided ... Piedras, Puerto Rico , where the ... Following a comprehensive onsite ... structural damage, temporary loss of power and minimal water ... manufacturing operations have resumed, and the company expects to ...
(Date:10/7/2017)... , Oct. 6, 2017   Provista, a ... than $100 billion in purchasing power, today announced a ... information. The Newsroom is the online home ... trends, infographics, expert bios, news releases, slideshows and events. ... to a wealth of resources at their fingertips, viewers ...
Breaking Medicine Technology: